Test Price
450 AED✅ Home Collection Available
Immunohistochemistry p53 Test in UAE | 450 AED | DHA Licensed Oncology Pathology
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited immunohistochemistry processing, delivering actionable p53 tumour suppressor protein status in FFPE tissue blocks.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival FFPE blocks; temperature-controlled chain of custody maintained. TAT: 5 days (standard biopsy), 7 days (large/complex tissue).
Clinical Guidance: Complimentary telephonic post-test clinical correlation session with a DHA-licensed specialist, ensuring result interpretation aligns with your oncology care plan.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Immunohistochemistry p53 Test determines the expression level and mutational status of the p53 tumour suppressor protein in formalin-fixed, paraffin-embedded (FFPE) tissue. In the UAE, this assay is integral to differentiating TP53-wild-type from mutant-pattern staining, guiding treatment stratification in breast, ovarian, colorectal, and Li-Fraumeni syndrome-associated cancers. The test utilises a validated dual-antibody panel (clone DO-7 / BP53-12) on an automated Leica Bond-max platform with FDA-cleared DAB detection and digital image analysis for objective scoring.
Why Our p53 IHC Test Leads UAE Clinical Practice
| Parameter | Our DHA-Accredited IHC | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity via ISO-validated clone DO-7 / BP53-12 antibody panel with double read | Standard single-antibody IHC, variable sensitivity ~92% |
| Methodology | Leica Bond-max automated staining with FDA-cleared DAB detection and digital image analysis | Manual staining, non-standardised scoring |
| Speed | 5-day routine TAT; urgent same-day preliminary verbal report available | 7-10 days, no expedited option |
Physician Insight & Safety Protocols
"An aberrant p53 immunostain – whether diffuse strong nuclear positivity or complete absence (null pattern) – is not a standalone diagnosis. I always integrate this result with the histopathology report, clinical history, and molecular genetics to guide targeted therapy or hereditary cancer workup. Your oncologist remains your primary decision-maker; this test is a tool, not a verdict."
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Important Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. Changes to chemotherapy or targeted agents must be based on full multidisciplinary board discussion.
Exclusion Criteria & Emergency Red Flags
- Unfixed, necrotic, or decalcified tissue samples – may yield false-negative staining.
- Patients who have received neoadjuvant radiation directly to the biopsy site within 14 days – antigen masking risk.
- Any sudden severe pain at biopsy site, bleeding, or signs of infection – proceed to nearest ER immediately.
- If you experience shortness of breath, facial swelling, or hives after biopsy collection, seek emergency care at once.
Patient FAQ & Clinical Guidance
1. What exactly does a p53 IHC test report tell my oncologist?
Snippet Killer: Your report reveals whether the p53 protein is wild-type (normal) or mutant-pattern, which helps classify tumour aggressiveness and predict response to chemotherapy or targeted drugs in breast, ovarian, and gastrointestinal cancers.
A wild-type pattern typically suggests a functional tumour suppressor, while overexpression or complete absence often correlates with TP53 gene mutation and may indicate eligibility for clinical trials or specific biologics. Your oncologist integrates this with the full pathology report and imaging.
2. How should I prepare for tissue submission to ensure accurate results?
Snippet Killer: You do not need to fast or change medications; simply ensure the formalin-fixed paraffin-embedded block (FFPE) or 10% formal-saline-preserved biopsy is accompanied by the original histopathology report, biopsy site, and clinical history.
Our logistics team can arrange Secure Medical Courier Solid Tissue Specimen Retrieval of the block at room temperature. No special patient preparation is required. For fresh biopsies, the referring physician will handle fixation. Please do not freeze the specimen.
3. Does a mutant p53 result mean I have Li-Fraumeni syndrome?
Snippet Killer: Not necessarily; somatic p53 mutations are extremely common in sporadic cancers, and a positive IHC alone requires genetic counselling and germline testing to confirm a hereditary cancer syndrome like Li-Fraumeni.
A mutant IHC pattern in tumour tissue often reflects an acquired somatic change. Only if blood or normal tissue testing reveals the same mutation should a diagnosis of Li-Fraumeni be considered. Our report includes a clear recommendation for geneticist referral when indicated.
4. How is the p53 IHC result reported and scored?
Snippet Killer: Results are reported as wild-type pattern (focal weak to moderate nuclear staining in a mosaic distribution), overexpression pattern (diffuse strong nuclear staining in >50% of tumour cells), or null pattern (complete absence of nuclear staining in tumour cells with positive internal control).
Each pattern carries distinct clinical implications. The report includes a semi-quantitative H-score (range 0-300) and a clear interpretive comment correlating the staining pattern with published literature on TP53 mutation status. Digital image analysis provides objective quantification.
5. What follow-up testing might be recommended after an abnormal p53 IHC result?
Snippet Killer: Depending on the staining pattern and clinical context, your oncologist may recommend TP53 gene sequencing by next-generation sequencing (NGS), homologous recombination deficiency (HRD) testing, or germline genetic counselling.
Overexpression or null patterns suggestive of TP53 mutation often prompt confirmatory molecular testing. In cases with early-onset breast cancer or multiple primary tumours, referral to a clinical geneticist for Li-Fraumeni syndrome evaluation is standard practice. Your care team will guide you through these steps.
UAE Regulatory & Data Privacy Adherence
UAE Regulatory Compliance: This test adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All telehealth communication is encrypted and DHA-compliant. Direct billing verification: WhatsApp +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry p53 (p53 IHC) – Tumour Suppressor Protein Expression Analysis |
| Price (AED) | 450 AED |
| Turnaround Time | 5 days (standard biopsy), 7 days (large/complex tissue); urgent same-day preliminary verbal report available |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or 10% formal-saline-preserved biopsy; archival tissue specimen – Secure Medical Courier Solid Tissue Specimen Retrieval |
| Methodology Used | Automated Immunohistochemistry (Leica Bond-max platform) with dual-antibody panel (clone DO-7 / BP53-12), FDA-cleared DAB detection, and digital image analysis with H-score quantification |
| ICD-10-CM Code | Z01.89 (Encounter for other specified special examinations) |
| LOINC Code | 62218-3 (p53 protein [interpretation] in Tissue by Immunohistochemistry) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians